Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
August 14, 2024 6:13 AM EDTBTIG analyst Thomas Shrader reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).
The analyst comments "The P2 trial for OV888 in CCM is expected to start in 2H24 and could rapidly establish POC. The lesions (complex blood vessel tangles) are clearly visible in patients and treatment with OV888 has the chance to resolve them (not certain but seen in animal models). Similarly, OV329 is a safer Vigabatrin by design, so confirming safety in humans is highly de-risking, we believe. We hosted OVID management at the recent BTIG... More
Ovid Therapeutics Inc. (OVID) Reports Q2 EPS of $0.12
August 13, 2024 8:13 AM EDTOvid Therapeutics Inc. (NASDAQ: OVID) reported Q2 EPS of $0.12, versus ($0.18) reported last year. Revenue for the quarter came in at $169 thousand, versus $75 thousand reported last year.
For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.
... More